Ascentage Pharma Group International (AAPG : NASDAQ)
Common Stock
$15.86
USD
+0.80 (5.31%)
Last updated: 2026-09-21
Get AAPG alerts:
AAPG
Ascentage Pharma Group International
WealthAwesomePerformance
1 Day
+5.31%
1 Week
-3.35%
1 Month
-6.71%
YTD
-7.20%
Key Statistics
Market Cap
$1.41B
52W High
$40.48
52W Low
$15.02
P/E Ratio
-
50 Day MA
$17.83
200 Day MA
$22.15
Beta
0.67
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/21/2026 | $15.91 | $16.17 | $15.82 | $15.86 | $15.86 | 17,353 |
| 9/18/2026 | $15.37 | $15.37 | $15.02 | $15.06 | $15.06 | 2,100 |
| 9/17/2026 | $15.32 | $15.44 | $15.09 | $15.37 | $15.37 | 3,162 |
| 9/16/2026 | $15.40 | $15.66 | $15.40 | $15.40 | $15.40 | 3,802 |
| 9/15/2026 | $16.10 | $16.10 | $16.00 | $16.00 | $16.00 | 4,287 |
| 9/14/2026 | $16.33 | $16.55 | $16.33 | $16.41 | $16.41 | 3,821 |
| 9/11/2026 | $16.20 | $16.29 | $16.03 | $16.10 | $16.10 | 7,144 |
| 9/10/2026 | $16.59 | $16.70 | $16.59 | $16.67 | $16.67 | 3,100 |
| 9/9/2026 | $17.23 | $17.33 | $17.22 | $17.31 | $17.31 | 1,600 |
| 9/8/2026 | $17.48 | $17.55 | $17.25 | $17.44 | $17.44 | 20,900 |
Analyst Price Targets
Based on 2 analysts covering AAPG · as of Sep 17, 2026
Wall Street analysts forecast AAPG stock price to rise 197.1% over the next 12 months.
Consensus
Strong Buy4.50 / 5.00
Avg. Target
US$47.13
+197.1% Upside
Current Price
US$15.86
Last close
Analyst Breakdown (2 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AAPG's historical volatility
30-Day Vol
53.1%
Annualized
90-Day Vol
54.8%
Annualized
Trend (90d)
-30.4%
Annualized drift
90d Mean
US$14.23
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$15.30 | US$12.74 – US$18.37 |
| 60 trading days | US$14.75 | US$11.39 – US$19.11 |
| 90 trading days | US$14.23 | US$10.36 – US$19.54 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Financials
- Revenue (TTM)
- $642.64M
- EBITDA
- $-1.34B
- Profit Margin
- -228.54%
- ROE (TTM)
- -236.63%
- EPS (Diluted)
- -2.36
- Book Value
- 0.89
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About AAPG.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| GRML | Greenland Mines Ltd | $9.42 | +230.53% |
| GLND | Greenland Energy Company Common Stock | $2.88 | +140.00% |
| BTTC | Black Titan Corporation | $0.79 | +117.75% |
| VEEE | Twin Vee Powercats Co | $17.24 | +100.93% |
| VRME | VerifyMe Inc | $1.38 | +73.58% |
| AVAT | Avalanche Treasury Corporation Class A Common Stock | $1.87 | +73.15% |
| INV | Innventure, Inc. | $0.88 | +47.26% |
| SVRN | OceanPal Inc. | $29.50 | +45.18% |